AMRI Acquires Gadea Pharmaceutical Group

Go back to AMRI Acquires Gadea Pharmaceutical Group

Albany Molecular Research (AMRI) Acquires Gadea Pharmaceutical in $174M Cash, Stock Deal

July 16, 2015 7:47 AM UTC

Albany Molecular Research (NASDAQ: AMRI) announced that it has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately-held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea's owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt.

"The acquisition of Gadea marks another milestone in our company's path towards becoming the preeminent supplier of custom and complex drug... More